Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) have received a consensus rating of “Buy” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $39.50.
Several research firms recently commented on PRTK. HC Wainwright boosted their price target on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a research note on Tuesday. Zacks Investment Research lowered Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $32.00 price objective on shares of Paratek Pharmaceuticals in a report on Thursday, March 30th. Robert W. Baird reaffirmed an “outperform” rating and set a $40.00 target price on shares of Paratek Pharmaceuticals in a report on Tuesday, April 4th. Finally, BTIG Research upped their target price on Paratek Pharmaceuticals from $47.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, April 4th.
Shares of Paratek Pharmaceuticals (PRTK) traded down 2.44% during trading on Monday, hitting $22.00. The stock had a trading volume of 1,208,494 shares. The stock’s 50 day moving average is $23.09 and its 200-day moving average is $19.41. The company’s market cap is $604.67 million. Paratek Pharmaceuticals has a 12-month low of $9.80 and a 12-month high of $26.10.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($1.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.20) by $0.06. The firm had revenue of $0.02 million during the quarter.
COPYRIGHT VIOLATION NOTICE: “Brokerages Set Paratek Pharmaceuticals, Inc. (PRTK) Target Price at $38.63” was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2017/07/21/brokerages-set-paratek-pharmaceuticals-inc-prtk-target-price-at-38-63.html.
In related news, VP Adam Woodrow sold 3,800 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total value of $89,604.00. Following the completion of the sale, the vice president now owns 69,500 shares of the company’s stock, valued at $1,638,810. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Evan Loh sold 4,351 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total transaction of $102,596.58. Following the completion of the sale, the chief operating officer now directly owns 112,783 shares of the company’s stock, valued at approximately $2,659,423.14. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,960 shares of company stock valued at $524,342. 4.90% of the stock is owned by corporate insiders.
Hedge funds have recently modified their holdings of the stock. Fox Run Management L.L.C. acquired a new position in shares of Paratek Pharmaceuticals during the second quarter worth about $200,000. Appleton Partners Inc. MA acquired a new position in shares of Paratek Pharmaceuticals during the second quarter worth about $220,000. Falcon Point Capital LLC acquired a new position in shares of Paratek Pharmaceuticals during the first quarter worth about $200,000. Russell Investments Group Ltd. acquired a new position in shares of Paratek Pharmaceuticals during the first quarter worth about $211,000. Finally, American International Group Inc. boosted its position in shares of Paratek Pharmaceuticals by 34.1% in the first quarter. American International Group Inc. now owns 11,111 shares of the specialty pharmaceutical company’s stock worth $214,000 after buying an additional 2,824 shares during the last quarter. 75.58% of the stock is owned by institutional investors and hedge funds.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.